Clinical Trials 2018-09-20T22:02:04+00:00

CLINICAL TRIALS

As the breadth of PH research expands, PHA is committed to keeping its members informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension. One mechanism to achieve this is to provide institutions and other research sponsors who are conducting multi-center clinical trials with an opportunity to describe relevant studies.

PH Clinical Trials

Trial Name: A phase 1 clinical trial of ABI-009, an mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH)
Sponsoring Institution: Aadi Bioscience LLC
Posted September 20, 2018
Read more

Trial Name: Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)
Sponsoring Institution: Liquidia Technologies
Posted July 20, 2018
Read more

Trial Name: Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension
Sponsoring Institution: Complexa, Inc.
Posted June 15, 2018
Read more

Trial Name: A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (INO) in Subjects with Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)
Sponsoring Institution: Bellerophon Therapeutics
Posted June 11, 2018
Read more

Trial Name: TOMORROW: A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension
Sponsoring Institution: Actelion, a Janssen Pharmaceutical Company of Johnson and Johnson
Posted May 31, 2018
Read more

Trial Name: ADAPT – A Patient Registry of the Real-world Use of Orenitram
Sponsoring Institution: United Therapeutics Corp.
Posted Dec. 6, 2017
Read more

Trial Name: A Study of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST
Sponsoring Institution: Reata Pharmaceuticals
Posted Nov. 14, 2017
Read more

Trial Name: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Sponsoring Institution: United Therapeutics Corporation
Posted Aug. 30, 2017
Read more

Trial Name: BAY63-2521 REplacing PDE-5i therapy evaLuated Against Continued PDE-5i therapy
Sponsoring Institution: Bayer U.S. LLC
Posted Aug. 15, 2017
Read more

Trial Name: A Study of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Sponsoring Institution: Reata Pharmaceuticals, Inc.
Posted Oct. 25, 2016
Read more

Trial Name: A multicenter, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added on to treprostinil, inhaled (Tyvaso) in subjects with pulmonary hypertension
Sponsoring Institution: Lung Biotechnology, PBC
Posted August 15, 2016
Read more

Trial Name: IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
Sponsoring Institution: Imperial College London
Posted August 15, 2016
Read more

Trial Name: A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY)
Sponsoring Institution: Eiger BioPharmaceuticals, Inc.
Posted June 10, 2016
Read more

Trial Name: Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) – LARIAT
Sponsoring Institution: Reata Pharmaceuticals
Posted Aug. 18, 2015
Read more

Trial Name: A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension
Sponsoring Institution: Arena Pharmaceuticals, Inc.
Posted Aug. 18, 2015
Read more

Trial Name: A multi-center, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added-on to treprostinil, inhaled (Tyvaso) in subjects with pulmonary arterial hypertension
Sponsoring Institution: Lung Biotechnology Inc. (subsidiary of United Therapeutics)
Posted April 19, 2014
Read more

Trial Name: Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects wth Pulmonary Arterial Hypertension
Sponsoring Institution: United Theraputics Corporation
Posted August 27, 2013
Read more

Trial Name: A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension
Sponsoring Institution: National Institutes of Health
Posted January 22, 2013
Read more

Trial Name: A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Sponsoring Institution: National Institutes of Health
Posted January 22, 2013
Read more

Trial Name: A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population with Pulmonary Arterial Hypertension
Sponsoring Institution: Eli Lilly and Company
Posted July 6, 2012
Read more

Trial Name: Determining the Prevalence and Progression of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia
Sponsoring Institution:
National Heart, Lung, and Blood Institute (NHLBI)
Posted December 15, 2011
Read more

Trial Name: A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sponsoring Institution: National Institute of Allergy and Infectious Diseases (NIAID)
Posted December 16, 2010
Read more